RHCPA
Asset Logo

Ramsay Health Care Limited

🇦🇺 ASX

Compare
Add to watchlist
👑 Overview

📈 Performance

💰 Dividends

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💰

0.00%
Annual dividend yield

Based on the most recent dividend

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

0
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Ramsay Health Care Ltd. is in the provision of healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in St Leonards, Victoria and currently employs 86,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, Elysium Healthcare and Ramsay Sime Darby. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.

📈 Performance

Price History

-0.13%

1M

10Y

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💰 Dividends

Payouts

💰 Annual Dividend Yield*

0.00%

💰 Annual Dividend Earnings Per $1,000 invested**

$0.00

💰 Most Recent Dividend Franked Percentage Estimate

100.00%

💰 Average Dividend Franked Percentage Estimate

100.00 %

💰 Dividend reinvestment

Learn more

* Based on the most recent dividend

** Calculated by multiplying the most recent dividend yield by $1,000

Dividend History

1Y

5Y

10Y

Graph

Table

Year
Yearly Dividend Earnings Per Share
Franking Estimate

2024

$0.00

0.00%

2023

$6.00

100.00%

2022

$3.78

100.00%

2021

$3.46

100.00%

2020

$3.81

100.00%

2019

$4.73

100.00%

2018

$4.84

100.00%

2017

$4.78

100.00%

2016

$5.04

100.00%

2015

$5.16

100.00%

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

0%
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🍃 Environmental, Social and Governance scores ℹ️

🌳

Environmental Score
59

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

🕊️

Social Score
47

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

⚖️

Governance Score
58

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

🤓 Advanced information

Technical Info

💰 Price*

$103.62

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in RHCPA

0

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in RHCPA

N/A
RHCPA investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

50k - 100k

Less than 50k

👶 Age of investors

18 - 25

26 - 34

35 - 90

🙋 Legal gender of investors

Female

Male

Pearlers who invest in RHCPA also invest in...

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

📊 Share price

$57.36 AUD

NULL GLOBAL

NULL SMART BETA

Find Out More

ETHI

ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.

📊 Share price

$12.45 AUD

NULL GLOBAL

NULL SMART BETA

NULL ETHICAL

NULL EX AUSTRALIA

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

📊 Share price

$120.79 AUD

NULL AUSTRALIA

NULL BETA

Cochlear Ltd. engages in the provision of implantable hearing solutions. The company is headquartered in Sydney, New South Wales and currently employs 4,500 full-time employees. The firm designs and offers products and accessories for adults or children. The firm operates through three segments: Cochlear implants, Services and Acoustics. The Company’s Cochlear implants segment offers Cochlear implant systems, including Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632). Its Services segment offers sound processor upgrades, accessories and other, including Cochlear Nucleus 7 Sound Processor and Cochlear Nucleus Kanso 2 Sound Processor. Its Acoustics segment offers Bone Conduction systems and Sound processor upgrades, including Cochlear Osia 2 System and Cochlear Baha 6 Max Sound Processor. Its products and accessories include Cochlear Nucleus System, Cochlear Baha System and Cochlear Baha Start. The firm operates in America; Europe, the Middle East and Africa (EMEA), and Asia Pacific.

📊 Share price

$247.39 AUD

NULL HEALTH

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. The company is headquartered in Melbourne, Victoria and currently employs 30,000 full-time employees. The Company’s areas of focus and exploration include rare and serious diseases, influenza vaccines, plasma collection, and therapies for iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus, and CSL Vifor. The CSL Behring segment manufactures, markets, and distributes plasma therapies (plasma products and recombinants). CSL Seqirus segment manufactures, markets, and distributes primarily influenza-related products and provides pandemic services to governments. The Company’s CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency, dialysis and nephrology and rare diseases. The Company’s geographical areas of operation include Australia, the United States of America, Germany, the United Kingdom, Switzerland, and China. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.

📊 Share price

$308.11 AUD

NULL HEALTH

Want more shares? Try these...

Red Hill Minerals Ltd. engages in the exploration of base metals, gold and iron ores properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-02-14. The firm is engaged in the exploration of iron ore, gold, and other minerals, including precious and base/battery metals. The firm is focused on the development of its channel iron deposits (CID) and rock quarrying opportunities in the Western Pilbara region of Western Australia. Its primary asset is Red Hill Iron Ore Joint Venture (RHIOJV). The firm holds a 100% interest in the Pannawonica channel iron project (CID), which is situated just north of the RHIOJV tenements. The firm has carried out studies for a quarrying concept based on porphyry rock outcrops at the Three Peaks site nearby to the Pannawonica Project.

📊 Share price

$4.70 AUD

Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm specializes in the development and delivery of non-invasive medical imaging software and services. The firm is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its portfolio includes Core Lab and artificial intelligence (AI) powered products to partner with clinicians and radiologists for diagnosis, and management of patients in a variety of clinical settings. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The firm's other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The firm also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart.

📊 Share price

$0.04 AUD

Regeneus Ltd. is regenerative medicine company. The firm uses stem cell technologies to develop a portfolio of novel cell-based therapies. The firm develops regenerative medicine products, including its two stem cell technologies, Progenza, which has been licensed to Kyocera for the treatment of knee osteoarthritis in Japan, and Sygenus, which is in pre-clinical-stage. Regenerative therapies seek to address unmet medical needs in the human health market, focusing on osteoarthritis, neuropathic pain, and various skin conditions, with its platform technologies Progenza and Sygenus. Progenza is a cellular therapy targeting pain and inflammation which uses Secretome to improve not only the resident tissue, but the Mesenchymal Signalling Cells (MSCs) themselves. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation. Sygenus is a cell-free topical serum and gel treatment for pain and inflammation.

📊 Share price

$0.01 AUD

Ramsay Health Care Ltd. is in the provision of healthcare services and the operation of hospitals and day surgery facilities. The company is headquartered in St Leonards, Victoria and currently employs 86,000 full-time employees. The Company’s segments include Asia Pacific, UK, France and Nordics. Its businesses include Ramsay Australia, Ramsay Sante, Ramsay UK, Elysium Healthcare and Ramsay Sime Darby. Ramsay Australia has over 73 private hospitals and day surgery units in Australia. Ramsay Sante is a private care provider in Europe and operates 443 multidisciplinary hospitals and clinics and 130 primary care centers across five countries. Ramsay UK has a network of 34 acute hospitals and day procedure centers in England providing a comprehensive range of clinical specialties to private and self-insured patients. Elysium Healthcare is an independent sector provider of specialist health and care services. Its four core service streams are mental health, neurological, learning disabilities and children and education.

📊 Share price

$57.00 AUD
Compare
Add to watchlist